Stocks on the Move: Meritor (NYSE:MTOR), Bruker Corporation (NASDAQ:BRKR), Marathon Oil Corporation (NYSE:MRO), Kite Pharma (NASDAQ:KITE), Fenix Parts (NASDAQ:FENX)


Meritor, Inc. (NYSE:MTOR) shares moved up 1.89% in last trading session and ended the day at $13.49. MTOR Gross Margin is 13.70% and its has a return on assets of 12.40%. Meritor, Inc. (NYSE:MTOR) quarterly performance is 4.65%. On 29 June, Meritor, Inc. (NYSE: MTOR), regretfully announced the passing of David Devonshire who died on June 25 at the age of 70. Devonshire served on Meritor’s board of directors since 2004 and was the presiding director from 2013 to 2015. He was the chair of the Audit Committee and a member of the Compensation and Management Development Committee.

Bruker Corporation (NASDAQ:BRKR) ended the last trading day at $20.37. Company weekly volatility is calculated as 2.04% and price to cash ratio as 6.99. Bruker Corporation (NASDAQ:BRKR) showed a weekly performance of -1.97%. On 30 June, Bruker Corporation (NASDAQ:BRKR) announced the release of its second-generation Inspire™ infrared (IR) nanocharacterization system, which features 10-nanometer spatial resolution infrared chemical mapping in an easy-to-use, laser-safe package. With IR EasyAlign™, Inspire simplifies scattering scanning near-field optical microscopy (sSNOM), a powerful technique for identifying chemical composition at the nanoscale.

On 02 July, Marathon Oil Corporation (NYSE:MRO) shares fell -0.23% and was closed at $25.73. MRO EPS growth in last 5 year was 7.10%. Marathon Oil Corporation (NYSE:MRO) year to date (YTD) performance is -7.68%. Marathon Oil Corporation (NYSE:MRO) announced it plans to issue its second quarter 2015 earnings news release on Wednesday, Aug. 5, after the close of U.S. financial markets.

Kite Pharma, Inc. (NASDAQ:KITE) shares moved up 2.47% in last trading session and ended the day at $65.07. KITE has a return on assets of -18.60%. Kite Pharma, Inc. (NASDAQ:KITE) quarterly performance is 20.61%. Kite Pharma, Inc., (NASDAQ:KITE) and The Leukemia & Lymphoma Society (LLS) announced that they have entered into a partnership to enhance the development of Kite’s lead product candidate, KTE-C19, for the treatment of patients with refractory aggressive non-Hodgkin lymphoma (NHL). KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.

Fenix Parts, Inc. (NASDAQ:FENX) caters to the Consumer Goods space. Its weekly performance is -9.39%. On the last day of trading company shares ended up $10.03. Fenix Parts, Inc. (NASDAQ:FENX) distance from 50-day simple moving average (SMA50) is -5.49%. On 29 June, Fenix Parts, Inc. (NASDAQ:FENX), filed its first quarter 2015 10-Q for Fenix Parts, Inc. (the designated accounting acquirer) and for the Beagell Group and Standard (the designated accounting co-predecessors), as such companies were described in the prospectus dated May 14, 2015 for Fenix Parts’ initial public offering (IPO).


Leave a Reply

Your email address will not be published. Required fields are marked *